Ad Hoc | Novartis

Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineOncologyMedical InnovationsCancerAd Hoc
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineAd HocAccess to Healthcare
Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

Ad hoc announcement pursuant to Art. 53 LR

NeuroscienceAd Hoc
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study

Ad hoc announcement pursuant to Art. 53 LR

Scientific DiscoveriesReimagine MedicineMedical InnovationsAd Hoc
Novartis maintains growth momentum and confirms FY’22 Group guidance

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent

Ad hoc announcement pursuant to Art. 53 LR

Ad Hoc
Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme

Annonce événementielle selon l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhere Produktivität

Ad-hoc-Mitteilung gemäss Art. 53 KR

Ad Hoc
Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

 Ad hoc announcement pursuant to Art. 53 LR

Ad Hoc